101 related articles for article (PubMed ID: 21304529)
1. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
[TBL] [Abstract][Full Text] [Related]
2. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract][Full Text] [Related]
3. Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.
Kantarjian HM; Martinelli G; Jabbour EJ; Quintás-Cardama A; Ando K; Bay JO; Wei A; Gröpper S; Papayannidis C; Owen K; Pike L; Schmitt N; Stockman PK; Giagounidis A;
Cancer; 2013 Jul; 119(14):2611-9. PubMed ID: 23605952
[TBL] [Abstract][Full Text] [Related]
4. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity.
Melisi D; Ossovskaya V; Zhu C; Rosa R; Ling J; Dougherty PM; Sherman BM; Abbruzzese JL; Chiao PJ
Clin Cancer Res; 2009 Oct; 15(20):6367-77. PubMed ID: 19808866
[TBL] [Abstract][Full Text] [Related]
5. Antineoplastic effects of pharmacological inhibitors of aurora kinases in CSF3R
Parducci NS; Garnique ADMB; Lima K; Carlos JAEG; Fonseca NP; de Miranda LBL; de Almeida BO; Rego EM; Traina F; Machado-Neto JA
Blood Cells Mol Dis; 2024 Jan; 104():102799. PubMed ID: 37839173
[TBL] [Abstract][Full Text] [Related]
6. Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
Ye H; Tong J; Liu J; Lin W; Zhang C; Chen K; Zhao J; Zhu W
Oncotarget; 2016 Jul; 7(28):43762-43778. PubMed ID: 27248325
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 - 2013).
Cheung CH; Sarvagalla S; Lee JY; Huang YC; Coumar MS
Expert Opin Ther Pat; 2014 Sep; 24(9):1021-38. PubMed ID: 24965505
[TBL] [Abstract][Full Text] [Related]
8. Compound HRAS/PIK3CA mutations in Chinese patients with alveolar rhabdomyosarcomas.
Liu CX; Li XY; Li CF; Chen YZ; Cui XB; Hu JM; Li F
Asian Pac J Cancer Prev; 2014; 15(4):1771-4. PubMed ID: 24641407
[TBL] [Abstract][Full Text] [Related]
9. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
Jeselsohn R; Yelensky R; Buchwalter G; Frampton G; Meric-Bernstam F; Gonzalez-Angulo AM; Ferrer-Lozano J; Perez-Fidalgo JA; Cristofanilli M; Gómez H; Arteaga CL; Giltnane J; Balko JM; Cronin MT; Jarosz M; Sun J; Hawryluk M; Lipson D; Otto G; Ross JS; Dvir A; Soussan-Gutman L; Wolf I; Rubinek T; Gilmore L; Schnitt S; Come SE; Pusztai L; Stephens P; Brown M; Miller VA
Clin Cancer Res; 2014 Apr; 20(7):1757-1767. PubMed ID: 24398047
[TBL] [Abstract][Full Text] [Related]
10. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Toy W; Shen Y; Won H; Green B; Sakr RA; Will M; Li Z; Gala K; Fanning S; King TA; Hudis C; Chen D; Taran T; Hortobagyi G; Greene G; Berger M; Baselga J; Chandarlapaty S
Nat Genet; 2013 Dec; 45(12):1439-45. PubMed ID: 24185512
[TBL] [Abstract][Full Text] [Related]
11. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
12. Cells Lacking the
Oser MG; Fonseca R; Chakraborty AA; Brough R; Spektor A; Jennings RB; Flaifel A; Novak JS; Gulati A; Buss E; Younger ST; McBrayer SK; Cowley GS; Bonal DM; Nguyen QD; Brulle-Soumare L; Taylor P; Cairo S; Ryan CJ; Pease EJ; Maratea K; Travers J; Root DE; Signoretti S; Pellman D; Ashton S; Lord CJ; Barry ST; Kaelin WG
Cancer Discov; 2019 Feb; 9(2):230-247. PubMed ID: 30373918
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.
Shah ET; Molloy C; Gough M; Kryza T; Samuel SG; Tucker A; Bhatia M; Ferguson G; Heyman R; Vora S; Monkman J; Bolderson E; Kulasinghe A; He Y; Gabrielli B; Hooper JD; Richard DJ; O'Byrne KJ; Adams MN
Br J Cancer; 2024 Apr; 130(7):1196-1205. PubMed ID: 38287178
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA analysis of Natural Killer cell-derived exosomes: the microRNA let-7b-5p is enriched in exosomes and participates in their anti-tumor effects against pancreatic cancer cells.
Di Pace AL; Pelosi A; Fiore PF; Tumino N; Besi F; Quatrini L; Santopolo S; Vacca P; Moretta L
Oncoimmunology; 2023; 12(1):2221081. PubMed ID: 37304055
[TBL] [Abstract][Full Text] [Related]
15. Targeting Myc-driven stress addiction in colorectal cancer.
Saeed H; Leibowitz BJ; Zhang L; Yu J
Drug Resist Updat; 2023 Jul; 69():100963. PubMed ID: 37119690
[TBL] [Abstract][Full Text] [Related]
16. Increased Aurora B expression reduces substrate phosphorylation and induces chromosomal instability.
Britigan EMC; Wan J; Sam DK; Copeland SE; Lasek AL; Hrycyniak LCF; Wang L; Audhya A; Burkard ME; Roopra A; Weaver BA
Front Cell Dev Biol; 2022; 10():1018161. PubMed ID: 36313574
[TBL] [Abstract][Full Text] [Related]
17. The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer.
Miller AL; Garcia PL; Fehling SC; Gamblin TL; Vance RB; Council LN; Chen D; Yang ES; van Waardenburg RCAM; Yoon KJ
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298684
[TBL] [Abstract][Full Text] [Related]
18. Aurora B kinase: a potential drug target for cancer therapy.
Ahmed A; Shamsi A; Mohammad T; Hasan GM; Islam A; Hassan MI
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2187-2198. PubMed ID: 34047821
[TBL] [Abstract][Full Text] [Related]
19. Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer.
Borah NA; Reddy MM
Molecules; 2021 Apr; 26(7):. PubMed ID: 33915740
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
